A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.

Trial Details

NCT ID

NCT07441460

Phase

PHASE3

Sponsor

Shanghai JMT-Bio Inc.

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

KN026
HB1801
Trastuzumab
Pertuzumab
Docetaxel
Epirubicin

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Voluntarily participate and sign the informed consent form.
Age ≥ 18 years.
ECOG performance status score of 0 or 1.
Histologically or cytologically confirmed invasive breast cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →